| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 512.4 | 432.4 | 444.4 | 372.1 |
Depreciation | -309.7 | -274.5 | -219.3 | -131.4 |
Tax paid | -87.9 | -63.7 | -104.2 | -67 |
Working capital | -34.39 | 497.9 | -955.5 | 480.2 |
Other operating items | ||||
Operating | 80.4 | 592.1 | -834.6 | 653.9 |
Capital expenditure | 483.5 | 442.8 | 1,356.5 | 328.8 |
Free cash flow | 563.9 | 1,034.9 | 521.89 | 982.7 |
Equity raised | 4,916.5 | 3,788.7 | 3,082.7 | 2,448.1 |
Investing | 332.1 | -74.4 | 618.7 | -382.4 |
Financing | 889.7 | 912.4 | 175.1 | 214.2 |
Dividends paid | 0 | 0 | 0 | 20 |
Net in cash | 6,702.2 | 5,661.6 | 4,398.4 | 3,282.6 |
The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.
The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.
This acquisition will also augment Syngene’s biologics capabilities and further strengthen its global presence.
The company's revenue from operations also grew healthily, up by 10.6% YoY to ₹943 crore, as against ₹853.5 crore in Q3 FY24.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
